Premium
EFFECT OF RENAL FAILURE ON THE PHARMACOKINETICS OF ETHYL LOFLAZEPATE (Victan®) IN MAN
Author(s) -
BA B.B.,
ILIADIS A.,
DURAND A.,
BERGER Y.,
NECCIARI J.,
CANO J.P.
Publication year - 1989
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1989.tb00025.x
Subject(s) - pharmacokinetics , metabolite , renal function , creatinine , medicine , plasma clearance , excretion , kidney , active metabolite , urinary system , endocrinology , chemistry , urology , pharmacology
Summary— The kinetics of ethyl loflazepate were studied in patients with various degrees of renal failure. A strong correlation was noted between urinary excretion of metabolite loflazepate and creatinine clearance. In contrast, elimination half‐life and total plasma clearance of the sum of loflazepate+descarboxyloflazepate seemed to be independent of the degree of renal impairment. These results indicate the absence of a risk of accumulation of the 2 main and active metabolites of ethyl loflazepate in patients with renal failure.